Literature DB >> 28497494

Global assays of fibrinolysis.

A Ilich1,2, I Bokarev3, N S Key1.   

Abstract

Fibrinolysis is an important and integral part of the hemostatic system. Acting as a balance to blood coagulation, the fibrinolytic system protects the body from unwanted thrombus formation and occlusion of blood vessels. As long as blood coagulation and fibrinolysis remain in equilibrium, response to injury, such as vessel damage, is appropriately regulated. However, alterations in this balance may lead to thrombosis or bleeding. A variety of methods have been proposed to assess fibrinolytic activity in blood or its components, but due to the complexity of the system, the design of a "gold standard" assay that reflects overall fibrinolysis has remained an elusive goal. In this review, we describe the most commonly used methods that have been described, such as thromboelastography (TEG and ROTEM), global fibrinolytic capacity in plasma and whole blood, plasma turbidity methods, simultaneous thrombin and plasmin generation assays, euglobulin clot lysis time and fibrin plate methods. All of these assays have strengths and limitations. We suggest that some methods may be preferable for detecting hypofibrinolytic conditions, whereas others may be better for detecting hyperfibrinolytic states.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  coagulation; euglobulin fraction; fibrinolysis; global assay; thromboelastography; turbidity assay

Mesh:

Substances:

Year:  2017        PMID: 28497494     DOI: 10.1111/ijlh.12688

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


  11 in total

1.  Resolution of acute lower extremity deep vein thrombosis with rivaroxaban compared to warfarin.

Authors:  Damon E Houghton; Alexander Lekah; Thanila A Macedo; David Hodge; Rayya A Saadiq; Yvonne Little; Ana I Casanegra; Robert D McBane; Waldemar E Wysokinski
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

Review 2.  Antifibrinolytic Therapy and Perioperative Considerations.

Authors:  Jerrold H Levy; Andreas Koster; Quintin J Quinones; Truman J Milling; Nigel S Key
Journal:  Anesthesiology       Date:  2018-03       Impact factor: 7.892

3.  Affimer proteins as a tool to modulate fibrinolysis, stabilize the blood clot, and reduce bleeding complications.

Authors:  Katherine J Kearney; Nikoletta Pechlivani; Rhodri King; Christian Tiede; Fladia Phoenix; Ramsah Cheah; Fraser L Macrae; Katie J Simmons; Iain W Manfield; Kerrie A Smith; Benjamin E J Spurgeon; Khalid M Naseem; Robert A S Ariens; Michael J McPherson; Darren C Tomlinson; Ramzi A Ajjan
Journal:  Blood       Date:  2018-12-13       Impact factor: 22.113

4.  Aqueous two-phase deposition and fibrinolysis of fibroblast-laden fibrin micro-scaffolds.

Authors:  Stephen Robinson; Jonathan Chang; Eric Parigoris; Louise Hecker; Shuichi Takayama
Journal:  Biofabrication       Date:  2021-04-07       Impact factor: 9.954

5.  Euglobulin clot lysis time reveals a high frequency of fibrinolytic activation in trauma.

Authors:  Anton Ilich; Vaibhav Kumar; Michael J Ferrara; Michael W Henderson; Denis F Noubouossie; Donald H Jenkins; Rosemary A Kozar; Myung S Park; Nigel S Key
Journal:  Thromb Res       Date:  2021-05-31       Impact factor: 10.407

6.  What concentration of tranexamic acid is needed to inhibit fibrinolysis? A systematic review of pharmacodynamics studies.

Authors:  Roberto Picetti; Haleema Shakur-Still; Robert L Medcalf; Joseph F Standing; Ian Roberts
Journal:  Blood Coagul Fibrinolysis       Date:  2019-01       Impact factor: 1.276

Review 7.  The relationship between pancreatic cancer and hypercoagulability: a comprehensive review on epidemiological and biological issues.

Authors:  Elena Campello; Anton Ilich; Paolo Simioni; Nigel S Key
Journal:  Br J Cancer       Date:  2019-07-22       Impact factor: 7.640

8.  Association between viscoelastic tests-guided therapy with synthetic factor concentrates and allogenic blood transfusion in liver transplantation: a before-after study.

Authors:  Raffael P C Zamper; Thiago C Amorim; Veronica N F Queiroz; Jordana D O Lira; Luiz Guilherme V Costa; Flavio Takaoka; Nicole P Juffermans; Ary S Neto
Journal:  BMC Anesthesiol       Date:  2018-12-22       Impact factor: 2.217

9.  Establishing a reference range for thromboelastograph parameters in the neonatal period.

Authors:  Qin Liu; Chunfen Xu; Xin Chen; Jia Wang; Zhunhui Ke; Hongbing Hu
Journal:  Int J Lab Hematol       Date:  2019-05-07       Impact factor: 2.877

10.  Methodological variations affect the release of VEGF in vitro and fibrinolysis' time from platelet concentrates.

Authors:  Leonel Alves de Oliveira; Tatiana Karla Borges; Renata Oliveira Soares; Marcelo Buzzi; Selma Aparecida Souza Kückelhaus
Journal:  PLoS One       Date:  2020-10-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.